GlassScriptPhysician profile
Ramez M Khoury
NPI 1780743682
$13,247.20
in general payments reported to CMS, 2019-2025
25 companies · $4,765 in 2025
The $4,765 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,237 · 2020: $25.50 · 2021: $688 · 2022: $1,704 · 2023: $2,350 · 2024: $2,477 · 2025: $4,765.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,753 · Consulting Fee: $1,650 · Travel and Lodging: $112 · Education: $76.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,753.18 |
| Consulting Fee | $1,650.00 |
| Travel and Lodging | $112.00 |
| Education | $76.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,585.02 | 2019-2025 | |
| Janssen Biotech, INC. | $2,887.85 | 2021-2025 | Tremfya, Stelara, Remicade |
| Gilead Sciences, INC. | $1,823.39 | 2019-2025 | Epclusa, Livdelzi |
| Madrigal Pharmaceuticals | $617.12 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $571.93 | 2021-2024 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $546.85 | 2021-2023 | Zeposia |
| Genzyme Corporation | $444.85 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $405.12 | 2021-2024 | Stelara |
| Phathom Pharmaceuticals, INC. | $348.65 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $328.55 | 2024-2025 | Dupixent |
| Lilly USA, LLC | $260.07 | 2024-2025 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $249.19 | 2019-2025 | Entyvio |
| Ardelyx, INC. | $220.16 | 2024 | Ibsrela |
| Regeneron Pharmaceuticals, INC. | $149.61 | 2024 | Dupixent |
| Novo Nordisk INC | $144.11 | 2025 | Wegovy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $130.34 | 2019-2023 | Watchman Flx |
| Ipsen Biopharmaceuticals, INC | $125.11 | 2025 | Iqirvo |
| Capsovision, INC. | $91.47 | 2025 | Capsocam Plus |
| Qol Medical, LLC | $83.67 | 2023 | Sucraid |
| Allergan, INC. | $75.56 | 2019-2020 | |
| Ucb, INC. | $74.86 | 2019 | |
| Ferring Pharmaceuticals INC. | $38.45 | 2019 | |
| Pfizer INC. | $16.37 | 2019 | |
| Merck Sharp & Dohme LLC | $16.16 | 2023 | Dificid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramez Khoury listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.